TSX:LEAF Investor Presentation March 2018

Size: px
Start display at page:

Download "TSX:LEAF Investor Presentation March 2018"

Transcription

1 TSX:LEAF Investor Presentation March 2018 Price Close (Mar 16, 2018): $19.34 Market Capitalization: $1.9 billion Basic and F.D. Shares: 99.8/109.6 million

2 Forward-Looking Information This Presentation contains forward-looking information within the meaning of applicable Canadian securities legislation which are based upon the Company s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as expect, likely, may, will, should, intend, anticipate, potential, proposed, estimate and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions may, would or will happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this Presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances as at the date hereof. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. In particular, we have made assumptions in respect of the build-out of the Bradford Facility; our competitive advantages; the expected legalization of cannabis use in Canada; the growth of our business and expansion into new markets; the development of new products and product formats for our cannabisbased pharmaceutical products; our ability to retain key personnel; our ability to continue investing in our infrastructure to support our growth; our ability to obtain and maintain financing on acceptable terms; the impact of competition; the changes and trends in the medical cannabis industry; and changes in laws, rules and regulations. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date hereof, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual actions, events, results, performance or achievements to differ materially from what is projected in forward-looking information, including but not limited to the risks described in greater detail in the section entitled Risk Factors in our most recent annual information form available on SEDAR at Although we have attempted to identify important factors that could cause actual actions, events, results, performance or achievements to differ materially from those described in forward-looking information, there may be other factors not presently known to us or that we presently believe are not material that may cause actions, events, results, performance or achievements to differ from those anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking information prove incorrect, actual actions, events, results, performance or achievements may vary materially from those expressed and implied by such statements contained in this Presentation. The purpose of forward-looking information is to provide the reader with a description of management s expectations, and such statements may not be appropriate for any other purpose. Accordingly, readers should not place undue reliance on forward-looking information. Although the Company believes that the expectations reflected in statements containing forward-looking information are reasonable, it can give no assurance that such expectations will prove to be correct. The Company disclaims any obligation to update any forward-looking information, whether as a result of new information or future events or results, except to the extent required by applicable securities laws. Non-IFRS Measures This Presentation refers to certain non-ifrs financial measures including Adjusted Product Contribution Margin, Cash Cost Per Gram Sold and Adjusted EBITDA (i.e., Adjusted Earnings Before Interest, Tax, Depreciation and Amortization). See the section entitled Non-IFRS Measures in our Management s Discussion and Analysis for the quarter ended December 31, 2017 available on SEDAR at These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing additional information regarding the Company s results of operations from management s perspective. Accordingly, non-ifrs measures should not be considered in isolation nor as a substitute for analysis of the Company s financial information reported under IFRS. 2

3 Setting the standard: Our Strategy PHARMACEUTICAL BREWERY BEVERAGE CONSUMER PRODUCTS Winners emerge and dominate 3

4 Decisions that set the standard Quality assurance Patient-centric approach Analytically-driven operations Ongoing innovation CANADIAN MEDICAL DRIED CANNABIS MARKET SHARE Total volume sold for the twelve month period ending Sep Licenses 2 17% MedReleaf Producing premium cannabis 83% Rest of the Licensed Producers 1) Source: Health Canada (most recent available data) and MedReleaf 2) Licenses held by producers as of March 6,

5 Setting the standard: Performance CASH COST PER GRAM GRAMS PRODUCED PER SQUARE FOOT 1 $3.50 $3.00 $2.50 ~ 300g CASH COST PER GRAM 1 $1.83 $2.00 $1.50 $1.00 Q2 F16 Q3 F16 Q4 F16 Q1 F17 Q2 F17 Q3 F17 Q4 F17 Q1 F18 Q2 F18 Q3 F18 1) For the three months ended December 31,

6 High growth with strong margins 109% DRIED CANNABIS Revenue Volume ($ millions) (kilograms) $8.05 $8.98 AVG. PRICE PER GRAM AVG. PRICE PER GRAM ,668 6% 39% % $ ,472 CASH COST PER GRAM EXTRACTS $11.83 AVG. PRICE PER GRAM ,689 2,501 $5.80 ADJ. CONTRIBUTION MARGIN PER GRAM F2016 F2017 YTDF17 YTDF18 F2016 F2017 YTDF17 YTDF18 Dried Cannabis Other Extracts Revenue and volume shipped for fiscal year ending March 31 and nine months ending December 31 65% ADJ. PRODUCT CONTRIBUTION MARGIN (THREE MONTHS ENDED DECEMBER 31, 2017) 6

7 Focused on profitability STRONG ADJ. EBITDA GENERATION ($ millions) F2016 F2017 YTDF17 YTDF18 Adj. EBITDA for the fiscal year ending March 31 and the nine months ending December 31 AVERAGE CONSUMPTION National 0.75 s GRAMS PER DAY MedReleaf 1.35 GRAMS PER DAY 1.8x NATIONAL CONSUMPTION AVERAGE National average based on Health Canada reports from January 1, 2017 to March 31, 2017 (the most recent information available from Health Canada). MedReleaf average from January 2017 to March Assumes that the national average remained the same for the period of January 2017 to March

8 55,000 sq. ft. facility 23,500 sq. ft. in cultivation 7,000 kg/yr capacity Markham facility 8

9 Facility expansion CULTIVATION CAPACITY (KG/YEAR) R&D LABS PHARMACEUTICAL MANUFACTURING 140,000 Total Bradford Facility 4x Markham 210,000 sq. ft. Indoor $40.3 million Revenue in F ,000 16,500 Total 28,000 28,000 9,500 7,000 7,000 7,000 7,000 M A R K H A M M A R K H A M + B R A D F O R D ( C U R R E N T ) Summer ,000 Total M A R K H A M + B R A D F O R D ( F U L L C A P A C I T Y ) M A R K H A M, B R A D F O R D, E X E T E R Exeter Facility 69 acres 1M sq. ft. Greenhouse 105,000 KG/Year 95 acres adjacent land 9

10 Business Overview 10

11 Indoor Greenhouse LIGHT CO2 NUTRIENTS HUMIDITY PRUNING RAPID SCALE LOWER UNIT COSTS TEMPERATURE MAXIMUM CONTROL FORMATION RAW MATERIAL FOR EXTRACTS AND NON-FLOWER RELATED PRODUCTS Higher quality Premium pricing 11

12 Quality assurance Fully-integrated cannabis producer, processor and distributor Only cannabis company in Canada ISO 9001 CERTIFIED & ICH-GMP COMPLIANCE CERTIFICATION 400+ QUALITY CONTROL CHECKS 12

13 Patient centric PATIENT SAFETY third-party tested for over 300 pesticides and other contaminants exclusive locking container PATIENT-DRIVEN PRODUCT DEVELOPMENT 1,000s of completed patient surveys patient-centric strain development FAST AND CONVENIENT DELIVERY same day shipping same day delivery in the GTA 89% customer satisfaction 13

14 Accessing channels, not just patients Chronic condition + payor Veterans (PTSD) Healthcare spending accounts Employee benefit plans Deploying analytics to identify high lifetime value patients whose conditions are shown to benefit from cannabis 14

15 Ongoing innovation: A science-driven approach Serving patients better Plant & process productivity 1,000s of data records collected over 10 years INNOVATE Plant genetics Plant molecular biology Bioprocess engineering Food science and nanotechnology Clinical microbiology and biochemistry Clinical research ITERATE University of Toronto Hamilton Health Sciences University of Waterloo Sunnybrook Health Sciences Centre 15

16 Our portfolio: Producing premium cannabis FIRST PLACE AWARDS PROPRIETARY GENETICS Tikun Olam lines Seed bank Breeding program (2017) (2017) (2016) (2017) ( ) (2017, 2015) SECOND PLACE AWARDS PRODUCT LINES 20+ dried products 6 oil products 4 capsule products 1 topical cream (2017) (2017) (2017) (2017) 16

17 Growth drivers MEDICAL NEW PRODUCTS RECREATIONAL INTERNATIONAL 17

18 Medical market is poised to grow tenfold Market growth ANNUAL CANADIAN MEDICAL CANNABIS MARKET $1.3 B Increasing Physician Education: Precise dosing for patients and physicians First Pharmacogenetics-Based Cannabis Compatibility Test PRESCRIBING 10-15% $407 M? DOSAGE? STRAIN Q317 Annualized* 2024 ~75,000 NON-PRESCRIBING *Based on Health Canada reported volume for the 3 months ending Sep at $7.50/gram Supply agreement with Shoppers Drug Mart 18

19 First licensed producer in Canada with an oil-capsule product and topical cream MEDRELEAF EXTRACTS % of Sales 21% Precise dosing for patients and physicians 3% Q3 F17 Q3 F18 Avidekel Midnight Sedamen Luminarium Proven ability to launch novel new products 19

20 $5-9B Canadian recreational market opportunity VALUE CORE PREMIUM BRAND Y BRAND Z Data driven and expert advised 20

21 Germany Supply agreement with Cannamedical Pharma GmbH Participating in the next phase of the domestic cultivation licensing process Exporting our expertise Focused on international partnerships that leverage our strategic value in order to replicate our Canadian success with local presence in 6 countries Brazil Completed first ICH-GMP certified commercial export and the country s first import of cannabis-oil Australia Partners have received cannabis cultivation and production licence 21

22 Management Neil Closner Chief Executive Officer 20 years of start-up, technology, and healthcare experience Former VP of Business Development at Mount Sinai Hospital Chairman of the Board of Cannabis Canada Association Eitan Popper President Over 15 years of international partnerships, large scale project development, and engineering experience Oversees infrastructure and cultivation Igor Gimelshtein Chief Financial Officer Over 7 years in private equity and investment banking Former VP at Birch Hill Equity Partners, a leading private equity firm in Canada Angelo Fefekos Vice President, Clinical Affairs and Quality Compliance Over 10 years experience in quality assurance and laboratory technology Previously managed a division of Diagnostic Medical Genetics and Allograft Technologies at Mount Sinai Hospital Management owns 7.8% 1 Donald Courtney Chief Operating Officer Over 20 years of global operations and supply chain experience in the wine, food, CPG and technology sectors. Previously at Vincor International, Pepsi Canada, and Mars Incorporated; served as COO of LG Electronics Canada Darren Karasiuk Vice President, Strategy Over 15 years of insight generation, marketing strategy and public affairs experience Previously VP, Insights and Advisory at Deloitte where he was a leader in the cannabis practice 1Based on million fully diluted shares outstanding 22

23 Setting the standard PHARMACEUTICAL BREWERY BEVERAGE CANNABIS Winners emerge and dominate 23

24 Investor Presentation March 2018

TSX:LEAF Investor Presentation December 2017 Top Licensed Producer

TSX:LEAF Investor Presentation December 2017 Top Licensed Producer TSX:LEAF Investor Presentation December 2017 Top Licensed Producer Price Close (Dec 7, 2017): $15.47 Market Capitalization: $1.5 billion Basic and F.D. Shares: 94.1/101.4 million Forward-Looking Information

More information

TSX:LEAF Investor Presentation October 2017

TSX:LEAF Investor Presentation October 2017 TSX:LEAF Investor Presentation October 2017 Price Close (Oct 6, 2017): $9.80 Market Capitalization: $890 million Basic and F.D. Shares: 90.8/93.2 million Forward-Looking Information This Presentation contains

More information

Investor Presentation August 23, 2017

Investor Presentation August 23, 2017 Investor Presentation August 23, 2017 Forward-Looking Information This Presentation contains forward-looking information within the meaning of applicable Canadian securities legislation which are based

More information

Nurturing Shareholder Growth

Nurturing Shareholder Growth JULY 2018 Nurturing Shareholder Growth EMBLEM CORP. TSXV: EMC DISCLAIMER This documentation is a presentation (the Presentation ) of general background information about Emblem Corp s., ( Emblem ) activities

More information

MEDRELEAF CORP. ANNUAL INFORMATION FORM. For the fiscal year ended March 31, 2017

MEDRELEAF CORP. ANNUAL INFORMATION FORM. For the fiscal year ended March 31, 2017 MEDRELEAF CORP. ANNUAL INFORMATION FORM For the fiscal year ended March 31, 2017 Dated: June 27, 2017 TABLE OF CONTENTS ANNUAL INFORMATION FORM... 1 FORWARD LOOKING INFORMATION... 1 CORPORATE STRUCTURE...

More information

Presented by: Eric Paul & Brad Rogers

Presented by: Eric Paul & Brad Rogers Improving the Quality of your Life Presented by: Eric Paul & Brad Rogers 1 A focused medical approach to meet the specific needs of the physicians and patients Standardized Products provide us the ability

More information

PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT

PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT Q2 2018 Investor Presentation PREMIUM January MEDICAL CANNABIS 10, 2018 POWERED BY SUN DISCLAIMER This documentation is a presentation (the Presentation ) of

More information

PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT

PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT PREMIUM MEDICAL CANNABIS POWERED BY SUNLIGHT Q2 2018 Investor Presentation PREMIUM January MEDICAL CANNABIS 10, 2018 POWERED BY SUN DISCLAIMER This documentation is a presentation (the Presentation ) of

More information

MEDRELEAF CORP. COMMON SHARES $

MEDRELEAF CORP. COMMON SHARES $ A copy of this preliminary prospectus has been filed with the securities regulatory authorities in each of the provinces and territories of Canada, but has not yet become final for the purpose of the sale

More information

The discussion and analysis in this MD&A is based on information available to management as of August 13, 2018.

The discussion and analysis in this MD&A is based on information available to management as of August 13, 2018. MANAGEMENT'S DISCUSSION AND ANALYSIS This following Management's Discussion and Analysis provides a review of the financial condition and results of operations for CannTrust Holdings Inc. (the "Company"

More information

I n v e s t o r P r e s e n t a t i o n A c q u i s i t i o n o f C a n n a F a r m s

I n v e s t o r P r e s e n t a t i o n A c q u i s i t i o n o f C a n n a F a r m s I n v e s t o r P r e s e n t a t i o n A c q u i s i t i o n o f C a n n a F a r m s July 30, 2018 TSX-V: VIVO OTCQB: ABCCF Disclaimer Certain information included in this presentation, which was prepared

More information

DISCLAIMER LIBERTY HEALTH SCIENCES INC. I INVESTORS PRESENTATION 2

DISCLAIMER LIBERTY HEALTH SCIENCES INC. I INVESTORS PRESENTATION 2 DISCLAIMER This documentation is a presentation (the Presentation ) of general background information about Liberty Health Sciences Inc. s ( Liberty Health Sciences ) activities current as of September

More information

DRIVING THE GLOBAL CANNABIS INDUSTRY. February 2019

DRIVING THE GLOBAL CANNABIS INDUSTRY. February 2019 DRIVING THE GLOBAL CANNABIS INDUSTRY February 2019 FORWARD-LOOKING STATEMENT This presentation contains forward-looking information within the meaning of applicable Canadian securities laws and forward-looking

More information

Investor Presentation. TSX Venture (OGI) OTCQX Best Market (OGRMF)

Investor Presentation. TSX Venture (OGI) OTCQX Best Market (OGRMF) Investor Presentation TSX Venture (OGI) OTCQX Best Market (OGRMF) Disclaimer & Cautionary Statements This document is current as of February 8, 2019, except where otherwise stated. The information contained

More information

DRIVING THE GLOBAL CANNABIS INDUSTRY. February 2018

DRIVING THE GLOBAL CANNABIS INDUSTRY. February 2018 DRIVING THE GLOBAL CANNABIS INDUSTRY February 2018 FORWARD-LOOKING STATEMENT This presentation contains forward-looking information within the meaning of applicable Canadian securities laws and forward-looking

More information

MANAGEMENT S DISCUSSION & ANALYSIS

MANAGEMENT S DISCUSSION & ANALYSIS MANAGEMENT S DISCUSSION & ANALYSIS This management discussion and analysis ( MD&A ) of the financial condition and results of operations of Aphria Inc., (the Company or Aphria ), is for the three and twelve

More information

VIVO CANNABIS INC. (formerly ABcann Global Corporation) Management s Discussion & Analysis. For the Three and Six Months Ended June 30, 2018

VIVO CANNABIS INC. (formerly ABcann Global Corporation) Management s Discussion & Analysis. For the Three and Six Months Ended June 30, 2018 VIVO CANNABIS INC. (formerly ABcann Global Corporation) Management s Discussion & Analysis For the Three and Six Months Ended June 30, 2018 August 29, 2018 Introduction This management s discussion and

More information

DRIVING THE GLOBAL CANNABIS INDUSTRY

DRIVING THE GLOBAL CANNABIS INDUSTRY DRIVING THE GLOBAL CANNABIS INDUSTRY The 14 th Regional Investments & Capital Markets Conference of the Jamaica Stock Exchange January 2019 FORWARD-LOOKING STATEMENT This presentation contains forward-looking

More information

A Powerful Strategic Combination

A Powerful Strategic Combination A Powerful Strategic Combination Forward Looking Statements This Presentation (the Document ) by Aurora Cannabis Inc. ( Aurora or the Company ) has been compiled by management of the Company solely for

More information

CREATING A NORTH AMERICAN CANNABIS POWERHOUSE APRIL 2019

CREATING A NORTH AMERICAN CANNABIS POWERHOUSE APRIL 2019 CREATING A NORTH AMERICAN CANNABIS POWERHOUSE APRIL 2019 DISCLAIMER This presentation contains forward-looking information within the meaning of applicable Canadian securities legislation and may also

More information

EMERALD HEALTH THERAPEUTICS, INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three and nine months ended September 30, 2017

EMERALD HEALTH THERAPEUTICS, INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three and nine months ended September 30, 2017 EMERALD HEALTH THERAPEUTICS, INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three and nine months ended September 30, 2017 Dated: November 15, 2017 - 2 - TABLE OF CONTENTS Forward-Looking Statements...

More information

Q INVESTOR PRESENTATION. A Global Cannabis Leader

Q INVESTOR PRESENTATION. A Global Cannabis Leader Q4 2018 INVESTOR PRESENTATION A Global Cannabis Leader July 31, 2018 This documentation is a presentation (the Presentation ) of general background information about Aphria Inc. s ( Aphria ) activities

More information

GLOBAL LEADER IN MEDICAL CANNABIS CREATED BY APHRIA AND NUUVERA COMBINATION

GLOBAL LEADER IN MEDICAL CANNABIS CREATED BY APHRIA AND NUUVERA COMBINATION GLOBAL LEADER IN MEDICAL CANNABIS CREATED BY APHRIA AND NUUVERA COMBINATION Combination capitalizes on Nuuvera s expansive international footprint, expanding network into Europe, Africa and the Middle

More information

THC Quarterly Update and Appendix 4C

THC Quarterly Update and Appendix 4C www.thcl.com.au ASX RELEASE (31 OCTOBER 2018) To be renamed THC Global Group Limited (subject to shareholder approval) THC Quarterly Update and Appendix 4C The Hydroponics Company Limited, to be renamed

More information

Emerald Health Therapeutics Reports 1 st Quarter 2018 Financial Results and Provides Corporate Update

Emerald Health Therapeutics Reports 1 st Quarter 2018 Financial Results and Provides Corporate Update Emerald Health Therapeutics Reports 1 st Quarter 2018 Financial Results and Provides Corporate Update Commences commercial production at its Pure Sunfarms Delta 3 joint venture greenhouse operation VICTORIA,

More information

DRIVING THE GLOBAL CANNABIS INDUSTRY. Bruce Linton Chairman, Founder & Co-CEO February 2019

DRIVING THE GLOBAL CANNABIS INDUSTRY. Bruce Linton Chairman, Founder & Co-CEO February 2019 DRIVING THE GLOBAL CANNABIS INDUSTRY Bruce Linton Chairman, Founder & Co-CEO February 2019 FORWARD-LOOKING STATEMENT This presentation contains forward-looking information within the meaning of applicable

More information

We Have A Good Thing Growing

We Have A Good Thing Growing This documentation is a presentation (the Presentation ) of general background information about Aphria Inc. s ( Aphria ) activities current as of April 16, 2018, unless stated otherwise. It is information

More information

POWERED BY SUNLIGHT 2016 ANNUAL REPORT

POWERED BY SUNLIGHT 2016 ANNUAL REPORT POWERED BY SUNLIGHT 2016 ANNUAL REPORT CONTENTS CHIEF EXECUTIVE OFFICER S MESSAGE 1 MANAGEMENT S DISCUSSION AND ANALYSIS 5 MANAGEMENT S RESPONSIBILITY FOR THE CONSOLIDATED FINANCIAL STATEMENTS 29 INDEPENDENT

More information

Condensed Interim Consolidated Financial Statements (In Canadian dollars) MEDRELEAF CORP. Three months ended June 30, 2017 and 2016 (Unaudited)

Condensed Interim Consolidated Financial Statements (In Canadian dollars) MEDRELEAF CORP. Three months ended June 30, 2017 and 2016 (Unaudited) Condensed Interim Consolidated Financial Statements (In Canadian dollars) MEDRELEAF CORP. Condensed Interim Consolidated Statements of Financial Position (In thousands of Canadian dollars) Assets June

More information

Corporate Presentation November 2017

Corporate Presentation November 2017 Investing In High Yield Businesses Around The Globe Corporate Presentation November 2017 Disclaimer This presentation ( Presentation ) is provided on the basis that neither LGC Capital Ltd) (the Company

More information

Investor Presentation March September 2017

Investor Presentation March September 2017 Investor Presentation March 2018 September 2017 Forward Looking Statements 2 This presentation contains certain "forward looking statements". These statements relate to future events or future performance

More information

(TSXV: LABS) MEDIPHARM LABS CORP. MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2018

(TSXV: LABS) MEDIPHARM LABS CORP. MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2018 (TSXV: LABS) MEDIPHARM LABS CORP. FOR THE YEAR ENDED DECEMBER 31, 2018 April 3, 2019 This management s discussion and analysis ( MD&A ) of the financial condition and performance of (the Company ) was

More information

VILLAGE FARMS INTERNATIONAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS/PURE SUNFARMS EXPANDING CANNABIS PRODUCTION AND SALES

VILLAGE FARMS INTERNATIONAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS/PURE SUNFARMS EXPANDING CANNABIS PRODUCTION AND SALES FOR IMMEDIATE RELEASE VILLAGE FARMS INTERNATIONAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS/PURE SUNFARMS EXPANDING CANNABIS PRODUCTION AND SALES NOT FOR DISTRIBUTION OVER UNITED STATES WIRE SERVICES

More information

MANAGEMENT S DISCUSSION AND ANALYSIS EMBLEM CORP. FOR THE THREE MONTHS ENDED MARCH 31, 2018

MANAGEMENT S DISCUSSION AND ANALYSIS EMBLEM CORP. FOR THE THREE MONTHS ENDED MARCH 31, 2018 OF EMBLEM CORP. FOR THE THREE MONTHS ENDED MARCH 31, 2018 This Management s Discussion and Analysis ( MD&A ) of Emblem Corp. and its subsidiary companies (collectively, Emblem or the Company ) provides

More information

MANAGEMENT S DISCUSSION AND ANALYSIS EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018

MANAGEMENT S DISCUSSION AND ANALYSIS EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 OF EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 This Management s Discussion and Analysis ( MD&A ) of Emblem Corp. and its subsidiary companies (collectively, Emblem or the Company ) provides

More information

EMERALD HEALTH THERAPEUTICS, INC.

EMERALD HEALTH THERAPEUTICS, INC. EMERALD HEALTH THERAPEUTICS, INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three and six months ended June 30, 2018 Dated: August 29, 2018-1 - TABLE OF CONTENTS Forward-Looking Statements... 3 Overview...

More information

Investor Presentation January CSE ticker: GW

Investor Presentation January CSE ticker: GW Investor Presentation January 2019 CSE ticker: GW 2 NOTICE TO RECIPIENT This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program,

More information

CANNABIS WHEATON INCOME CORP. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, Stated in Canadian Funds

CANNABIS WHEATON INCOME CORP. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, Stated in Canadian Funds CANNABIS WHEATON INCOME CORP. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2018 Stated in Canadian Funds DATE: MAY 30, 2018 For the Period Ended March 31, 2018

More information

Investor Presentation February September 2017

Investor Presentation February September 2017 Investor Presentation February 2018 September 2017 Forward looking statements 2 This presentation contains certain "forward looking statements". These statements relate to future events or future performance

More information

THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017

THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017 THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017 Montreal, Canada February 7, 2018 Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year

More information

DRIVING THE GLOBAL CANNABIS INDUSTRY. Bruce Linton Founder, Chairman & Co-CEO November 2018

DRIVING THE GLOBAL CANNABIS INDUSTRY. Bruce Linton Founder, Chairman & Co-CEO November 2018 DRIVING THE GLOBAL CANNABIS INDUSTRY Bruce Linton Founder, Chairman & Co-CEO November 2018 FORWARD-LOOKING STATEMENT This presentation contains forward-looking information within the meaning of applicable

More information

GLG LIFE TECH CORPORATION REPORTS 2017 FIRST QUARTER FINANCIAL RESULTS

GLG LIFE TECH CORPORATION REPORTS 2017 FIRST QUARTER FINANCIAL RESULTS GLG Life Tech Corporation * Suite 100, 10271 Shellbridge Way, Richmond, B.C. Canada V6X 2W8 TSX: GLG GLG LIFE TECH CORPORATION REPORTS 2017 FIRST QUARTER FINANCIAL RESULTS Vancouver, B.C. May 12, 2017

More information

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) OF EMBLEM CORP. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 NOTICE OF UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

More information

CORPORATE PRESENTATION CANADA S CANNABIS COMPANY

CORPORATE PRESENTATION CANADA S CANNABIS COMPANY CORPORATE PRESENTATION CANADA S CANNABIS COMPANY LEGAL DISCLAIMER NOTICE TO RECIPIENT This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete

More information

STRATEGIC PARTNERSHIP WITH ALTRIA TO ACCELERATE GROWTH AND INNOVATION

STRATEGIC PARTNERSHIP WITH ALTRIA TO ACCELERATE GROWTH AND INNOVATION NASDAQ / TSX TICKER CRON STRATEGIC PARTNERSHIP WITH ALTRIA TO ACCELERATE GROWTH AND INNOVATION December 2018 Disclaimers & Cautionary Statements C R O N O S G R O U P INC. This communication contains forward-looking

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION OCTOBER 2018 CSE: CHM OTCQB: CHMJF FORWARD LOOKING STATEMENTS This corporate document contains forward-looking statements and forward-looking information (collectively, forward-looking

More information

DOJA Cannabis Company Limited (Formerly SG Spirit Gold Inc.)

DOJA Cannabis Company Limited (Formerly SG Spirit Gold Inc.) DOJA Cannabis Company Limited (Formerly SG Spirit Gold Inc.) Management s Discussion and Analysis For the three and six months ended September 30, 2017 Introduction This management s discussion and analysis

More information

Canopy Growth Corporation (Formerly Tweed Marijuana Inc.)

Canopy Growth Corporation (Formerly Tweed Marijuana Inc.) Canopy Growth Corporation (Formerly Tweed Marijuana Inc.) Management s Discussion and Analysis of the Financial Condition and Results of Operations For the three and six months ended September 30, 2015

More information

CRONOS GROUP INC. Management s Discussion and Analysis of Financial Condition and Results of Operations. For the First Quarter Ended March 31, 2018

CRONOS GROUP INC. Management s Discussion and Analysis of Financial Condition and Results of Operations. For the First Quarter Ended March 31, 2018 CRONOS GROUP INC. Management s Discussion and Analysis of Financial Condition and Results of Operations For the First Quarter Ended March 31, 2018 (in thousands of Canadian dollars) GENERAL MATTERS This

More information

SUPREME PHARMACEUTICALS INC.

SUPREME PHARMACEUTICALS INC. SUPREME PHARMACEUTICALS INC. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL RESULTS For the nine months ended March 31, 2016 Date: May 30, 2016 SUPREME PHARMACEUTICALS INC. Management Discussion and

More information

Investor Presentation January 2018

Investor Presentation January 2018 Investor Presentation January 2018 2 Forward-looking Information This presentation contains forward-looking information within the meaning of applicable securities laws. Forward-looking information may

More information

THE AURORA STANDARD QUALITY AGILITY INNOVATION EXECUTION EXPANSION. Acquisition of CanniMed Therapeutics. March 2018

THE AURORA STANDARD QUALITY AGILITY INNOVATION EXECUTION EXPANSION. Acquisition of CanniMed Therapeutics. March 2018 THE AURORA STANDARD QUALITY AGILITY INNOVATION EXECUTION EXPANSION Acquisition of CanniMed Therapeutics March 2018 Forward Looking Statements This presentation (the Document ) by Aurora Cannabis Inc. (

More information

Highlights for Village Farms U.S. Hemp/CBD Initiative

Highlights for Village Farms U.S. Hemp/CBD Initiative Village Farms International Reports Fourth Quarter and Year End 2018 Financial Results Cannabis Joint Venture, Pure Sunfarms, Generates Positive Net Income in First Full Quarter of Sales and for the Full

More information

Zenabis November 21, 2018

Zenabis November 21, 2018 Zenabis November 21, 2018 Disclaimers IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING. The information contained in this document has been prepared by Sun Pharm Investments Ltd. ( Sun Pharm or

More information

AURORA CANNABIS INC. MANAGEMENT S DISCUSSION AND ANALYSIS. For the three-month period ended September 30, 2017

AURORA CANNABIS INC. MANAGEMENT S DISCUSSION AND ANALYSIS. For the three-month period ended September 30, 2017 MANAGEMENT S DISCUSSION AND ANALYSIS For the three-month period ended September 30, 2017 This Management s Discussion and Analysis ( MD&A ) reports on the consolidated financial condition and operating

More information

ianthus Capital Acquires Medical Cannabis Business of GrowHealthy Holdings, Marking Full-Scale Entry into Fast Growing Florida Market

ianthus Capital Acquires Medical Cannabis Business of GrowHealthy Holdings, Marking Full-Scale Entry into Fast Growing Florida Market January 17, 2018 ianthus Capital Acquires Medical Cannabis Business of GrowHealthy Holdings, Marking Full-Scale Entry into Fast Growing Florida Market Company to Host a Conference Call at 4:20 PM ET on

More information

BLISSCO CANNABIS CORP. MANAGEMENT DISCUSSION AND ANALYSIS Nine Months Ended October 31, 2018

BLISSCO CANNABIS CORP. MANAGEMENT DISCUSSION AND ANALYSIS Nine Months Ended October 31, 2018 MANAGEMENT DISCUSSION AND ANALYSIS Nine Months Ended 1.1 Date This Management Discussion and Analysis ( MD&A ) of BlissCo Cannabis Corp. (the Company or BlissCo ) has been prepared by management as of

More information

INVESTOR PRESENTATION. June 01, 2018 CSE: CALI OTCQB: FNNZF

INVESTOR PRESENTATION. June 01, 2018 CSE: CALI OTCQB: FNNZF INVESTOR PRESENTATION June 01, 2018 CSE: CALI OTCQB: FNNZF DISCLAIMER Cautionary Note Regarding Forward-Looking Information These materials include forward-looking statements. Such statements are based

More information

ORGANIGRAM HOLDINGS INC. $35,003,000 9,860,000 Common Shares

ORGANIGRAM HOLDINGS INC. $35,003,000 9,860,000 Common Shares No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This short form prospectus constitutes a public offering of these securities

More information

ALMONTY ACHIEVES POSITIVE EBITDA FROM MINING OPERATIONS (1) OF $12,702,000 AND NET INCOME OF $0.04 PER SHARE IN Q3 OF FY 2018

ALMONTY ACHIEVES POSITIVE EBITDA FROM MINING OPERATIONS (1) OF $12,702,000 AND NET INCOME OF $0.04 PER SHARE IN Q3 OF FY 2018 ALMONTY ACHIEVES POSITIVE EBITDA FROM MINING OPERATIONS (1) OF $12,702,000 AND NET INCOME OF $0.04 PER SHARE IN Q3 OF FY 2018 Toronto August 13, 2018 Almonty Industries Inc. ( Almonty or the Company )

More information

Namaste Technologies Inc. Management Discussion and Analysis Three and six months ended February 28, 2018

Namaste Technologies Inc. Management Discussion and Analysis Three and six months ended February 28, 2018 Namaste Technologies Inc. Management Discussion and Analysis Three and six months ended 1 This Management s Discussion and Analysis ( MD&A ) has been prepared as at and should be read in conjunction with

More information

Management s Discussion & Analysis

Management s Discussion & Analysis Management s Discussion & Analysis For the three and six month interim period ended June 30, Medworxx Solutions Inc. 700 121 Richmond St W. Toronto, ON M5H 2K1 This Management s Discussion and Analysis

More information

Investor Presentation May September 2017

Investor Presentation May September 2017 Investor Presentation May 2018 September 2017 Forward Looking Statements 2 This presentation contains certain "forward looking statements". These statements relate to future events or future performance

More information

Golden Leaf Reports Fiscal First Quarter 2018 Results

Golden Leaf Reports Fiscal First Quarter 2018 Results Golden Leaf Reports Fiscal First Quarter 2018 Results Toronto, Ontario May 30, 2018 Golden Leaf Holdings Ltd. ( Golden Leaf or the Company ) (CSE:GLH) (OTCQB:GLDFF), a leading cannabis oil solutions company

More information

EMERALD HEALTH THERAPEUTICS, INC.

EMERALD HEALTH THERAPEUTICS, INC. EMERALD HEALTH THERAPEUTICS, INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three months ended March 31, 2018 Dated: May 28, 2018-1 - TABLE OF CONTENTS Forward-Looking Statements... 3 Overview... 5 Recent

More information

The Hydropothecary Corporation. Company Overview. Management Discussion & Analysis. For the three and nine months ending April 30, 2017 and 2016

The Hydropothecary Corporation. Company Overview. Management Discussion & Analysis. For the three and nine months ending April 30, 2017 and 2016 For the three and nine months ending April 30, 2017 and 2016 This management discussion and analysis ( MD&A ) of the financial condition and results of operations of The Hydropothecary Corporation and

More information

CRONOS GROUP INC. MANAGEMENT S DISCUSSION AND ANALYSIS

CRONOS GROUP INC. MANAGEMENT S DISCUSSION AND ANALYSIS CRONOS GROUP INC. MANAGEMENT S DISCUSSION AND ANALYSIS For the Three and Nine Months Ended September 30, 2017 (in Canadian dollars) INTRODUCTION This Management Discussion and Analysis ( MD&A ) provides

More information

Management s Discussion & Analysis

Management s Discussion & Analysis Management s Discussion & Analysis For the three month interim period ended March 31, 2014 Medworxx Solutions Inc. 700-121 Richmond St W. Toronto, ON M5H 2K1 This Management s Discussion and Analysis (

More information

ABcann Global Corporation. (formerly Panda Capital Inc.) Management s Discussion & Analysis

ABcann Global Corporation. (formerly Panda Capital Inc.) Management s Discussion & Analysis ABcann Global Corporation (formerly Panda Capital Inc.) Management s Discussion & Analysis For the Three and Six Months Ended June 30, 2017 Introduction This management s discussion and analysis ( MD&A

More information

SLEEP COUNTRY CANADA ACQUISITION OF ENDY. INVESTOR PRESENTATION November 30, 2018

SLEEP COUNTRY CANADA ACQUISITION OF ENDY. INVESTOR PRESENTATION November 30, 2018 SLEEP COUNTRY CANADA ACQUISITION OF ENDY INVESTOR PRESENTATION November 30, 2018 DISCLAIMERS Forward-looking Information Certain information in this presentation contains forward-looking information and

More information

POCML 4 INC. Management s Discussion and Analysis. (a Capital Pool Corporation) For the Quarter Ended: March 31, Date of Report: May 30, 2018

POCML 4 INC. Management s Discussion and Analysis. (a Capital Pool Corporation) For the Quarter Ended: March 31, Date of Report: May 30, 2018 POCML 4 INC. (a Capital Pool Corporation) Management s Discussion and Analysis For the Quarter Ended: March 31, 2018 Date of Report: May 30, 2018 This management s discussion and analysis of the financial

More information

GLG LIFE TECH CORPORATION REPORTS 2017 SECOND QUARTER FINANCIAL RESULTS

GLG LIFE TECH CORPORATION REPORTS 2017 SECOND QUARTER FINANCIAL RESULTS GLG Life Tech Corporation * Suite 100, 10271 Shellbridge Way, Richmond, B.C. Canada V6X 2W8 TSX: GLG GLG LIFE TECH CORPORATION REPORTS 2017 SECOND QUARTER FINANCIAL RESULTS Vancouver, B.C. August 14, 2017

More information

CANOPY GROWTH CORPORATION

CANOPY GROWTH CORPORATION CANOPY GROWTH CORPORATION MANAGEMENT S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2016 AND 2015 FEBRUARY 13, 2017 Canopy

More information

Access a New Frontier

Access a New Frontier Access a New Frontier Investing in marijuana using etfs Horizons Marijuana Life Sciences Index ETF (hmmj) Horizons Emerging Marijuana Growers Index ETF (hmjr) Innovation is our capital. Make it yours.

More information

CANOPY GROWTH CORPORATION

CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (IN CANADIAN DOLLARS) TABLE OF CONTENTS Condensed interim consolidated statements of financial position... 1 Condensed interim consolidated

More information

A digital financial brand for the next generation of Canadians

A digital financial brand for the next generation of Canadians A digital financial brand for the next generation of Canadians Mogo Finance Technology Inc. NOVEMBER 2015 Forward-Looking Statements Forward-Looking Information: This document contains forward looking

More information

Auxly Corporate Overview

Auxly Corporate Overview Auxly Corporate Overview 2018 Financial and Operational Highlights Legal Disclaimer The information provided herein is not intended to provide financial, tax, legal or accounting advice. The contents hereof

More information

DISCLAIMER LIBERTY HEALTH SCIENCES INC. I INVESTORS PRESENTATION 2

DISCLAIMER LIBERTY HEALTH SCIENCES INC. I INVESTORS PRESENTATION 2 DISCLAIMER This documentation is a presentation (the Presentation ) of general background information about Liberty Health Sciences Inc. s ( Liberty Health Sciences ) activities current as of July 7, 2017.

More information

E N WAV E C O R P O R AT I O N C O R P O R A T E P R E S E N T A T I O N

E N WAV E C O R P O R AT I O N C O R P O R A T E P R E S E N T A T I O N E N WAV E C O R P O R AT I O N C O R P O R A T E P R E S E N T A T I O N G L O B A L L E A D E R I N V A C U U M M I C R O W A V E D E H Y D R A T I O N T E C H N O L O G Y. E N W A V E. N E T 2 D I S

More information

INVESTOR DAY Annual Meeting of Shareholders

INVESTOR DAY Annual Meeting of Shareholders INVESTOR DAY 2014 Annual Meeting of Shareholders May 10, 2017 Dr. Jack Shevel Chairman INVESTOR DAY 2014 Annual Meeting of Shareholders May 10, 2017 David Cutler President & Chief Executive Officer Forward

More information

For personal use only

For personal use only 26 October 2018 ASX Code: MXC September 2018 Quarterly Activity Report Key milestones achieved towards MXC achieving its goal as a leading medicinal cannabis Bio-Pharma company GMP Certification and Manufacturing

More information

VILLAGE FARMS INTERNATIONAL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES COMMENCEMENT OF COMMERCIAL-SCALE GROWING AT DELTA 3 GREENHOUSE

VILLAGE FARMS INTERNATIONAL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES COMMENCEMENT OF COMMERCIAL-SCALE GROWING AT DELTA 3 GREENHOUSE FOR IMMEDIATE RELEASE VILLAGE FARMS INTERNATIONAL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES COMMENCEMENT OF COMMERCIAL-SCALE GROWING AT DELTA 3 GREENHOUSE NOT FOR DISTRIBUTION OVER UNITED

More information

Second Quarter 2018 Earnings Call

Second Quarter 2018 Earnings Call Second Quarter 2018 Earnings Call Alan Kestenbaum Executive Chairman and CEO Don Newman Chief Financial Officer August 1, 2018 1 Disclaimer Caution Regarding Forward-Looking Statements and Key Assumptions

More information

THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. PROVIDES SHAREHOLDER UPDATE AND ANNOUNCES $10 MILLION NON-BROKERED FINANCING

THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. PROVIDES SHAREHOLDER UPDATE AND ANNOUNCES $10 MILLION NON-BROKERED FINANCING THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. PROVIDES SHAREHOLDER UPDATE AND ANNOUNCES $10 MILLION NON-BROKERED FINANCING Dear Shareholders, It is with great pleasure that I address you today as shareholders

More information

Theratechnologies Announces Financial Results for Third Quarter of 2017

Theratechnologies Announces Financial Results for Third Quarter of 2017 Theratechnologies Announces Financial Results for Third Quarter of 2017 Montreal, Canada October 5, 2017 Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the

More information

Tilray, Inc. Reports Second Quarter 2018 Earnings

Tilray, Inc. Reports Second Quarter 2018 Earnings Reports Second Quarter 2018 Earnings August 28, 2018 Revenue rises 95.2% to US$9.7 million in second quarter and 75.2% to US$17.6 million in first half of 2018 Tilray medical cannabis products now available

More information

IR PRESENTATION January 2019

IR PRESENTATION January 2019 IR PRESENTATION January 2019 FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning

More information

C O R P O R A T E P R E S E N T A T I O N APRIL 2018 C$ RQB

C O R P O R A T E P R E S E N T A T I O N APRIL 2018 C$ RQB C O R P O R A T E P R E S E N T A T I O N APRIL 2018 C$ RQB U$ RVVQF 1IT F O R W A R D L O O K I N G S T A T E M E N T This presentation contains forward-looking statements. These forward-looking statements

More information

Corporate Presentation

Corporate Presentation Corporate Presentation April 2018 CSE: CRZ OTCQX: CNNRF INVESTOR PRESENTATION STOCK DISCLAIMERS Forward Looking Information This investor presentation dated March 2018 (the Presentation ) contains forward-looking

More information

EMBLEM CORP. MANAGEMENT S DISCUSSION AND ANALYSIS For the year ended December 31, 2016

EMBLEM CORP. MANAGEMENT S DISCUSSION AND ANALYSIS For the year ended December 31, 2016 MANAGEMENT S DISCUSSION AND ANALYSIS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Management s Discussion and Analysis [ MD&A ] of Emblem Corp. [ Emblem or the Company ] contains forward-looking

More information

APHRIA INC. MANAGEMENT S DISCUSSION & ANALYSIS

APHRIA INC. MANAGEMENT S DISCUSSION & ANALYSIS APHRIA INC. This management discussion and analysis ( MD&A ) of the financial condition and results of operations of Aphria Inc., (the Company or Aphria ), is for the three and six months ended November

More information

Stone Ridge Exploration Corp. Suite Howe Street Vancouver, B.C. V6C 2C2

Stone Ridge Exploration Corp. Suite Howe Street Vancouver, B.C. V6C 2C2 NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Stone Ridge Exploration

More information

Enhancing profitable growth in our value-added poultry business. Investor Presentation November 26, 2018

Enhancing profitable growth in our value-added poultry business. Investor Presentation November 26, 2018 Enhancing profitable growth in our value-added poultry business Investor Presentation November 26, 2018 2 Forward-looking Statements and non-ifrs Measures This presentation contains statements made by

More information

June Investor Presentation

June Investor Presentation June 2014 Investor Presentation Safe Harbor Certain statements included herein, including guidance and those that express management's objectives and the strategies to achieve those objectives, as well

More information

MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 HLS

MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 HLS MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 HLS Therapeutics Inc. ( HLS or the Company ) was formed on March 12, 2018 by the amalgamation of HLS Therapeutics

More information

AURORA CANNABIS INC. MANAGEMENT S DISCUSSION AND ANALYSIS. For the three and six-month periods ended December 31, 2017

AURORA CANNABIS INC. MANAGEMENT S DISCUSSION AND ANALYSIS. For the three and six-month periods ended December 31, 2017 MANAGEMENT S DISCUSSION AND ANALYSIS For the three and six-month periods ended December 31, 2017 This Management s Discussion and Analysis ( MD&A ) reports on the consolidated financial condition and operating

More information

Investment for the Canadian Recreational Cannabis Market

Investment for the Canadian Recreational Cannabis Market CANOPY GROWTH CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS: DRIVING READINESS FOR THE CANADIAN RECREATIONAL CANNABIS MARKET Total licensed footprint exceeding 2.4 million sq.

More information

SCOTIABANK BACK TO SCHOOL CONFERENCE. September 15, 2015

SCOTIABANK BACK TO SCHOOL CONFERENCE. September 15, 2015 SCOTIABANK BACK TO SCHOOL CONFERENCE September 15, 2015 DISCLAIMER STATEMENT Forward Looking Information This presentation contains information about Hudson s Bay Company including its direct and indirect

More information

Canopy Growth to Acquire Hiku Brands to Strengthen Retail and Brand Portfolio

Canopy Growth to Acquire Hiku Brands to Strengthen Retail and Brand Portfolio Canopy Growth to Acquire Hiku Brands to Strengthen Retail and Brand Portfolio July 10, 2018 SMITHS FALLS, ON & TORONTO Canopy Growth Corporation ( Canopy Growth ) (TSX:WEED) (NYSE:CGC) and Hiku Brands

More information

PRESS RELEASE RELEASE DATE: May 1, 2018

PRESS RELEASE RELEASE DATE: May 1, 2018 5N Plus Reports Financial Results for the First Quarter Ended March 31, 2018 PRESS RELEASE RELEASE DATE: May 1, 2018 Montreal, Québec, May 1, 2018 5N Plus Inc. (TSX:VNP) ( 5N Plus or the Company ), a leading

More information